NICE confirms Lucentis choice for wet AMD
This article was originally published in Scrip
Guidance from the National Institute for health and Clinical Excellence(NICE), recommending that patients in England and Wales with wet age-related macular degeneration (AMD) receiveNovartis's Lucentis (ranibizumab, licensed from Genentech), has been confirmed after unsuccessful appeals. Pfizerwas unable to convince the institute to alter its negative assessment of Macugen (pegaptinib) in the same indication,
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.